Vorasidenib maximum plasma concentration (Cmax) and AUC increased approximately proportionally over the dose range of 10 to 200 mg (0.2 to 4 times the exposure of the highest approved recommended dosage) following once daily administration of single and multiple doses. At the highest approved recommended dosage, steady state mean (CV%) Cmax is 133 ng/mL (73%) and AUC is 1,988 h•ng/mL (95%). Steady state is achieved within 28 days of once daily dosing and the mean accumulation ratio of AUC is 4.4.
Absorption
The median (minimum, maximum) time to maximum plasma concentrations (tmax) at steady state is 2 hours (0.5 to 4 hours).
The mean absolute bioavailability of vorasidenib is 34%.
Food Effect
A high-fat and high-calorie (total 800-1,000 calories, of which 500-600 from fat) meal increased vorasidenib Cmax 3.1-fold and AUC 1.4-fold, compared to the fasting conditions.
A low-fat and low-calorie (total 400-500 calories, of which 100-125 from fat) meal increased vorasidenib Cmax 2.3-fold and AUC 1.4-fold, compared to the fasting conditions.
Distribution
The mean (CV%) volume of distribution at steady state of vorasidenib is 3,930 L (40%).
The protein binding is 97% in human plasma independent of vorasidenib concentrations in vitro.
The brain tumor-to-plasma concentration ratio is 1.6.
Elimination
The mean (CV%) steady state terminal half-life is 10 days (57%) and oral clearance is 14 L/h (56%).
Metabolism
Vorasidenib is primarily metabolized by CYP1A2 with minor contributions from CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A. Non-CYP pathways may contribute up to 30% of its metabolism.
Excretion
Following a single oral radiolabeled dose of vorasidenib, 85% of the dose was recovered in feces (56% unchanged) and 4.5% was recovered in urine.
Specific Populations
No clinically significant effects on the pharmacokinetics of vorasidenib were observed based on age (16 to 75 years), sex, race (White, Black or African American, Asian, American Indian/Alaskan Native, Native Hawaiian or Other Pacific Islander), ethnicity (Hispanic and non-Hispanic), body weight (43.5 to 168 kg), mild or moderate hepatic impairment (Child-Pugh Class A or B) or CLcr >40 mL/min (as Cockcroft-Gault). The pharmacokinetics of vorasidenib has not been studied in patients with severe hepatic impairment (Child-Pugh Class C), in patients with CLcr ≤40 mL/min or in patients with renal impairment who require dialysis.
Pediatric Patients
The exposure of vorasidenib in pediatric patients ≥12 years of age is predicted to be within range of that observed in adults at the approved recommended dosage.
Drug Interaction Studies
Clinical Studies and Model-Informed Approaches
Effect of Other Drugs on Vorasidenib
Strong and Moderate CYP1A2 Inhibitors: Concomitant use of ciprofloxacin (moderate CYP1A2 inhibitor) increased vorasidenib plasma Cmax 1.3-fold and AUC 2.5-fold.
Concomitant use with fluvoxamine (strong CYP1A2 inhibitor) is predicted to increase vorasidenib Cmax and AUC by ≥5-fold.
Moderate CYP1A2 Inducers: Concomitant use with phenytoin or rifampicin (moderate CYP1A2 inducers) is predicted to decrease vorasidenib steady-state Cmax by 30% and AUC by 40%.
Gastric Acid Reducing Agents: No clinically significant difference in vorasidenib pharmacokinetics was observed following concomitant use with omeprazole (an acid-reducing agent).
Effect of Vorasidenib on Other Drugs
CYP3A Substrates: Concomitant use of multiple doses of vorasidenib with CYP3A substrates is predicted to decrease the concentrations of these substrates.
UGT1A4 Substrate: No clinically significant difference in lamotrigine pharmacokinetics was observed following the administration of lamotrigine with multiple doses of vorasidenib.
P-gp and BCRP Substrates: No clinically significant difference in the pharmacokinetics of digoxin (P‑gp substrate) or rosuvastatin (BCRP substrate) is predicted when used concomitantly with vorasidenib.
In vitro Studies
Vorasidenib is an inducer of CYP2B6, CYP2C8, CYP2C9, CYP2C19 and CYP3A and UGT1A4.
Vorasidenib is not a substrate of P-gp, BCRP, or OATP1B1 and OATP1B3.
Vorasidenib is an inhibitor of BCRP. Vorasidenib does not inhibit P-gp and OATP1B1.